文献速递肝病炎症性肠病消化道肿瘤与早癌

免疫抑制与生物调节剂治疗相关的乙型肝炎再激活:当前概念、管理策略与未来方向

Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.
PubMed 文献 · Gastroenterology · 2017-02-20

综述指出,当前或既往暴露于乙型肝炎病毒(HBV)者接受癌症化疗、免疫抑制或生物制剂治疗时,HBV再激活是重要致病和致死原因;文章系统更新了危险因素、分子机制、预防与管理,并给出未来研究建议。

要点

  • 当前或既往暴露于HBV者接受免疫抑制或生物制剂治疗时存在HBV再激活风险。
  • HBV再激活与化疗、风湿病、恶性肿瘤、炎症性肠病、皮肤病及移植相关治疗有关。
  • 综述汇总了HBV再激活的危险因素、分子机制、预防和管理策略。

核心结论

  • HBV再激活是当前或既往暴露于HBV者接受免疫抑制和生物制剂治疗时的重要致病和致死原因。

研究设计与样本

  • 综述,系统更新HBV再激活的当前概念、危险因素、分子机制、预防和管理,并提供未来研究建议。

主要发现

  • 当前或既往暴露于HBV的人群均存在HBV再激活风险。
  • 由于HBV尚无治愈和根除疗法,普通人群中存在大量HBV再激活风险个体。
  • 癌症化疗、免疫抑制或生物制剂治疗(用于风湿病、恶性肿瘤、炎症性肠病、皮肤病或实体器官/骨髓移植)时HBV再激活尤其值得关注。
  • 随着新型靶向生物制剂的出现,理解某些治疗更易导致HBV再激活的机制变得重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatitis B reactivation associated with immune-suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with current or prior exposure to hepatitis B virus (HBV) infection. The population at risk for HBV reactivation includes those who either currently are infected with HBV or have had past exposure to HBV. Because curative and eradicative therapy for HBV is not currently available, there is a large reservoir of individuals at risk for HBV reactivation in the general population. HBV reactivation with its potential consequences is particularly a concern when these people are exposed to either cancer chemotherapy, immunosuppressive or biologic therapies for the management of rheumatologic conditions, malignancies, inflammatory bowel disease, dermatologic conditions, or solid-organ or bone marrow transplantation. With the advent of newer and emerging forms of targeted biologic therapies, it has become important to understand the mechanisms whereby certain therapies are more prone to HBV reactivation. This review provides a comprehensive update on the current concepts, risk factors, molecular mechanisms, prevention, and management of hepatitis B reactivation. In addition, we provide recommendations for future research in this area.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017. PMID: 28219691. doi:10.1053/j.gastro.2017.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。